Loomis Sayles & Co. L P Has $81.11 Million Stock Position in Insmed Incorporated (NASDAQ:INSM)

Loomis Sayles & Co. L P lessened its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 2.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,174,791 shares of the biopharmaceutical company’s stock after selling 35,396 shares during the period. Loomis Sayles & Co. L P owned about 0.66% of Insmed worth $81,108,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC increased its stake in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC lifted its position in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 248 shares during the last quarter. Spire Wealth Management acquired a new stake in shares of Insmed in the 4th quarter valued at approximately $47,000. Smartleaf Asset Management LLC grew its position in Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in shares of Insmed in the fourth quarter valued at approximately $86,000.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on INSM. Morgan Stanley increased their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. JPMorgan Chase & Co. upped their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Guggenheim reissued a “buy” rating and set a $101.00 price objective on shares of Insmed in a report on Tuesday, February 25th. Finally, HC Wainwright restated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

Insmed Trading Down 2.5 %

Shares of INSM opened at $76.57 on Thursday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm’s fifty day moving average is $77.97 and its two-hundred day moving average is $73.91. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The stock has a market cap of $13.86 billion, a PE ratio of -13.70 and a beta of 1.28.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Research analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insider Activity

In other Insmed news, CFO Sara Bonstein sold 18,322 shares of Insmed stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total value of $1,471,439.82. Following the completion of the sale, the chief financial officer now directly owns 118,863 shares of the company’s stock, valued at approximately $9,545,887.53. The trade was a 13.36 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the transaction, the chief executive officer now directly owns 384,960 shares of the company’s stock, valued at $26,885,606.40. This trade represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 550,957 shares of company stock valued at $42,992,528. Insiders own 4.60% of the company’s stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.